Publications
Triptorelin 6-month Formulation Shows Good Efficacy and Safety in Patients with Central Precocious Puberty (CPP)
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1
Characterization of Two Novel Oncogenic FGFR2 Fusions Sensitive to the FGFR Selective Inhibitor Debio 1347 in Cholangiocarcinoma
Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC)…
Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations